Cetuximab-conjugated bovine serum albumin nanoparticles loaded with doxorubicin demonstrated a significant in vitro cytotoxicity effect against EGFR-overexpressing colon cancer cells (RKO cells) compared to EGFR-under-expressing colon cancer cells (LS174 T cells), as well as decreased doxorubicin efflux in cetuximab-conjugated BSA nanoparticles. Here, ALB is linked to colonic neoplasm.